Zensho Holdings7550.T
Hamasushi prints ¥320bn of revenue in FY March 2026 against Sukiya at ¥314bn ; the second leg has overtaken the first by sales while the market continues to read the dossier as a Sukiya recovery story. Hamasushi segment operating margin at 8.4% on the year sits next to Sukiya at 3.0% post-contamination. The consolidated forward P/E of 23.8x reads on FY March 2026 earnings still depressed by the Sukiya trough. The diagnostic is two consecutive Sukiya quarterly margin prints recovering toward 7% between November 2026 and May 2027.
Hamasushi at ¥320bn revenue and 8.4% segment OP margin produces segment OP of ¥26.8bn in FY March 2026.
Sukiya at ¥314bn revenue and a 7% mid-cycle margin reconstructs to ¥22bn against the FY March 2026 trough print of ¥9.3bn.
The Prepared Food segment — the MMD infrastructure — prints ¥27.4bn OP at 12.3% margin on ¥222bn of intersegment revenue, structurally the highest-margin pillar.
Consolidated market cap at spot is ¥1,260bn. Normalised consolidated OP recovers to ¥95–105bn against the FY March 2026 print of ¥81bn.
The economic mass of the dossier has shifted. Hamasushi revenue at ¥320.3bn for the fiscal year ended 31 March 2026 has crossed Sukiya at ¥314.5bn for the first time. Hamasushi prints 8.4% segment OP margin on the year — close to Sukiya's pre-incident 8.3% — while Sukiya prints 3.0% under the contamination trough. The consensus forward P/E of 23.8x anchors on FY March 2027 earnings that still embed a partial Sukiya drag.
The dossier rests on what the structural mid-cycle Sukiya segment margin is once the contamination cycle clears. The consensus reading reconstructs to 7–8% along the Sushiro 2014 recovery template — Market Rule 3 in the sub-industry framework calls for 12–18 month Japanese recoveries from food-safety shocks. The variant reading is that the contamination at Sukiya touched the Mass Merchandising Distribution infrastructure shared across the group, not a single-store kitchen, and that the permanent margin loss on Sukiya post-recovery is 100–200 bps versus the 8.3% baseline — mid-cycle reconstructs to 6.5–7% rather than 7.5–8%.
Two consecutive Sukiya semester margin prints between November 2026 and May 2027 — H2 FY March 2027 reported May 2027, and the cumulative H1 FY March 2027 reported November 2026 — close the debate empirically. Sustained prints above 7% confirm the consensus template. Two consecutive prints below 5% reframe the dossier toward permanent margin loss.
The variant view that does the work in this memo is on the second leg. Hamasushi at +28.9% revenue growth FY March 2026 over FY March 2025, with segment OP margin sustained near 8.4% as the format scales, is a compounder leg now larger than Sukiya by revenue. The market prices it inside a consolidated multiple that anchors on the Sukiya recovery narrative. The cellular reading separates the legs.
Position framing is patient ownership at current levels, gated by the four Sukiya prints and by the first granular International segment disclosure expected at the FY March 2026 annual filing. Sizing at entry is contained by the FCF yield floor on the consolidated entity. Conviction is moderate.
The eleven-year window from FY March 2016 to FY March 2026 reads as three sequential regimes. Pre-international consolidation through FY March 2018, with the domestic banner portfolio scaling under the Zensho holding structure and net debt stable at ¥124bn. International expansion through M&A from FY March 2019 to FY March 2024, with Snowfox sushi kiosks UK/US, Advamed US, Lovary Australia, and the Hema China retail food JV absorbed sequentially — revenue scaled from ¥608bn to ¥966bn and net debt rose from ¥124bn to ¥238bn. Operational matter-of-record FY March 2025 to FY March 2026, with revenue scaling further to ¥1,264bn and EBIT to ¥81bn, and the Sukiya contamination incident materialised in late FY March 2026.
| Inflection | FY Mar 2016Pre-international | FY Mar 2019Pre-COVID | FY Mar 2021COVID trough | FY Mar 2024Inflation regime peak | FY Mar 2026Contamination year |
|---|---|---|---|---|---|
| Revenue (¥bn) | 525.7 | 607.7 | 595.0 | 965.8 | 1,264.1 |
| EBIT (¥bn) | 12.1 | 18.8 | 12.1 | 53.7 | 81.4 |
| EBIT margin | 2.3% | 3.1% | 2.0% | 5.6% | 6.4% |
| EBITDA margin | ~6% | ~6% | ~6% | ~9% | 10.8% |
| FCF (¥bn) | 9.1 | 11.6 | 9.4 | 45.9 | 23.2 |
| Capex (¥bn) | −16.4 | −21.6 | −20.3 | −40.1 | −78.0 |
| Net debt (¥bn) | 128.5 | 155.4 | 190.7 | 237.9 | 252.7 |
| Net income (¥bn) | 4.0 | 9.9 | 2.3 | 30.7 | 45.8 |
| EPS basic (¥) | 27.1 | 67.9 | 14.8 | 195.4 | 275.9 |
Source: Data pack, 19 May 2026. FY March 2026 = year ended 31 March 2026 (reported actuals). EBITDA margins for FY March 2016, 2019, 2021, 2024 reconstructed from EBITDA/Revenue triangulation.
The cumulative five-year FCF FY March 2022–2026 of ¥126.5bn (against current market cap of ¥1,260bn) was redeployed into capex and acquisitions rather than buybacks. The Shareholder Alignment pillar at 3.0/5 captures this directly.
The engine runs on dispersion between three economic pillars now visible in the segment disclosure. Sukiya at ¥314.5bn revenue and 3.0% segment OP margin in FY March 2026, against 8.3% in FY March 2025 — the contamination trough is fully booked. Hamasushi at ¥320.3bn revenue and 8.4% segment OP margin, with revenue growth at +28.9% year-on-year — the compounder leg, now larger than Sukiya by sales. Prepared Food at ¥221.9bn intersegment revenue and 12.3% segment OP margin — the MMD infrastructure, structurally the highest-margin pillar, captured in the financial statements as a separate reporting segment from FY March 2026 onward.
The MMD infrastructure integrated vertically into the banner network is the moat. Each operating banner draws on shared sourcing, transformation and logistics — beef sourcing direct from Australia, US and Mexico for Sukiya, fish procurement at scale for Hamasushi, central-kitchen distribution. The consolidated gross margin of 54.3% in FY March 2026 against the mature foodservice typical range of 30–40% measures the moat directly. The contamination incident at Sukiya in late FY March 2026 traces back to the same vertical infrastructure — the cost of vertical integration on the upside is the concentration of the operational risk on the downside.
The critical input costs are beef for Sukiya, fish for Hamasushi, and labour multi-banner. The 2022–2024 cycle cumulated approximately +30% on beef wholesale prices and +25% on labour Japan via Shunto wage rounds — partially absorbed through pricing pass-through at Sukiya, where +25% cumulative beef bowl menu pricing was absorbed without measurable traffic destruction. The MMD contracts and the diversified sourcing geography moderate the input volatility versus competitors with shorter procurement chains. No material financial hedging is disclosed.
FCF/EBITDA ratio FY March 2026 of 17.1% reflects elevated capex at ¥78bn against EBITDA of ¥136bn, with capex/D&A at 1.43x signalling continued growth investment. Across the cycle, cumulative FCF FY March 2022–2026 of ¥126.5bn against cumulative EBIT of ¥241bn produces a 52% cycle conversion ratio when adjusted for the FY March 2026 growth-capex peak. Mid-cycle FCF reconstructs to ¥60–80bn after capex normalisation toward 1.1–1.2x D&A. The FCF yield is the floor of the valuation. At cost-of-equity 7%, equity is worth ¥1,000–1,140bn at FCF normalised ¥70bn / 0.07, or ¥6,200–7,100 per share. The base case fair-value lower bound is anchored on this arithmetic.
The Mass Merchandising Distribution infrastructure integrated vertically into the banner network is the structural advantage of the dossier and unmatched in the sub-industry coverage. Consolidated gross margin of 54.3% in FY March 2026 against the foodservice mature range of 30–40% measures the operating spread captured upstream. The Prepared Food segment standalone disclosure at 12.3% OP margin on ¥222bn of intersegment revenue makes the moat visible as a separate operating economic unit for the first time. The pricing power demonstrated at Sukiya — +25% cumulative beef bowl pricing absorbed 2022–2024 without measurable traffic destruction — is the most material pricing-power observation in the sub-industry. The same vertical integration produced the contamination incident at Sukiya in late FY March 2026 ; concentration of input control is concentration of operational risk.
The Ogawa-era M&A track record across 2018–2024 brought four overseas platforms — Advamed US, Snowfox UK/US, Lovary Australia, Hema China JV with Alibaba. Total assets tripled over the eleven-year window from ¥278bn to ¥960bn. Segmental margin disclosure on the international portfolio has not been published granularly to date — the FY March 2026 annual filing expected in May 2026 is the first occasion for that disclosure to surface. The quality-control failure on the MMD chain that produced the Sukiya contamination is the most material governance signal in the eleven-year window. Capital allocation has favoured M&A and capex over share buyback ; the eleven-year window shows no material repurchase against ¥126.5bn of cumulative five-year FCF. The pillar is the second cardinal because the path of the dossier from FY March 2027 onward turns on whether the international portfolio margin discloses at 5–7% or stays implicit at 2–4%.
Sukiya defensive gyudon volume base proven through 2022–2024 pricing pass-through. Hamasushi compounder leg at +28.9% revenue FY March 2026. Drag from post-contamination Sukiya traffic uncertainty.
Gross margin 54.3% structurally anchored in MMD. ROIC lease-adjusted in 7–8% range. Drag from capex/D&A 1.43x FY March 2026 and FCF conversion of 17% on EBITDA.
Dividend yield at 0.96%, DPS ¥75 in FY March 2026 against ¥50 in FY March 2024. Net debt deleveraging marginal since the 2024 peak. No material buyback over the eleven-year window.
Above Skylark (14/25, mature pure-Japan saturated), below Food & Life (19–20/25, organic compounder with proven Overseas execution), comparable to Toridoll (16.5/25, SOTP dislocation under different mechanics). The grade supports an archetype A leverage-compounder multiple of 18–22x forward P/E on normalised AOP. The grade does not yet support a premium to that range without granular disclosure of International segment margins.
Is the Sukiya mid-cycle segment margin 7–8% or 5–7% after the contamination clears ?
Do the international platforms disclose at 5–7% or stay implicit at 2–4% ?
The Snowfox UK/US, Advamed, Lovary Australia and Hema China JV platforms have been consolidated since FY March 2023 but segment margin disclosure has not been granular. The Global Fast Food segment at 2.9% OP margin in FY March 2026 captures part of the international footprint. Base case expects the FY March 2026 annual filing to disclose International margin in the 4–5% range, consistent with a gradual synergy materialisation. The framework assigns 20–30% probability to disclosure below 3% combined with an impairment announcement of ¥30bn or more across FY March 2027–2028.
Does FX yen mean-reversion compress the normalised earnings power ?
The 2022–2024 yen depreciation cycle from ¥108 to ¥152 to the dollar amplified reported earnings on the international portfolio, estimated at 25–35% of the EBITDA Overseas growth on the window. Consolidated EBIT margin at 6.4% FY March 2026 embeds the FX tailwind. The mid-cycle reconstruction at ¥132 USD/JPY reduces the consolidated EBIT margin by 25–50 bps to roughly 5.9–6.2%. The framework treats this as structural compression absorbed in the multiple.
At ¥7,842 spot and forward P/E of 23.8x on FY March 2027 consensus, the market is pricing Zensho as a Japanese leverage compounder with full Sukiya recovery to roughly 7% segment margin by H2 FY March 2028 and gradual international synergy materialisation. The FY March 2028 implied multiple of 20.7x lands inside the archetype A 18–22x corridor on normalised earnings. Two implicit anchors do the work. The contamination at Sukiya is treated as a localised event with a Sushiro-2014 timeline and no permanent margin loss. The international platforms are assumed to disclose at 4–5% segment margin without impairment. Neither anchor is yet observable in the published segments.
Three triggers, of which any one is sufficient. Two consecutive Sukiya semester prints below 5% confirm systemic margin loss of 200–300 bps. International segment disclosure below 3% combined with impairment guidance of ¥30bn or more on Snowfox or Lovary or Hema. Full yen mean-reversion to ¥110–120 USD/JPY compresses normalised EBIT margin to 5.0–5.5%. AOP normalised reconstructs to ¥65–75bn and the multiple compresses to 15–17x. The FCF yield anchors the floor.
Sukiya semester margin recovers along the Japanese template to 7–8% by H2 FY March 2028 with permanent loss of 100 bps absorbed. Hamasushi maintains +15 to +20% revenue growth FY March 2027–2028 with segment margin in the 8.0–8.5% range. International segment discloses at 4–5%. Yen mean-reverts partially to ¥138–142 USD/JPY. AOP normalised ¥89–92bn at 20x P/E. The cellular reading delivers ¥8,200–8,800.
Sukiya recovers rapidly to 8–9% segment margin by H1 FY March 2028 with pre-incident baseline restored. Hamasushi sustains +20 to +25% revenue growth and margin expansion toward 9–10% with format scaling. International discloses above 5% with concrete synergy commentary. A material share buyback of ¥30bn or more is announced across FY March 2027–2028. AOP normalised ¥105–115bn at 24x P/E. Three of four triggers sequenced over 18–24 months.
| KPI | Latest value | Status | What it tells us |
|---|---|---|---|
| Sukiya segment OP margin | 3.0% (FY Mar 2026) | Cardinal | The number governing the dossier alongside Hamasushi growth. Two consecutive semester prints between November 2026 and May 2027 close Debate 1. Sustained above 7% validates base case ; below 5% on two consecutive prints triggers bear case. |
| Hamasushi segment revenue growth | +28.9% YoY (FY Mar 2026) | Cardinal | The compounder leg. Now larger than Sukiya by revenue. Sustained at +15% or above FY March 2027–2028 confirms the structural mass-shift of the dossier. |
| First granular International segment disclosure | expected May 2026 | Trigger | Annual filing expected to publish International segment margin granularly for the first time. Disclosure above 4% confirms base case ; below 3% combined with impairment guidance triggers bear. |
| Prepared Food segment OP margin | 12.3% (FY Mar 2026) | Asymmetric | The MMD infrastructure made visible. Maintains the structural moat reading. Compression below 10% would signal cost discipline erosion on the vertical chain. |
| Consolidated EBIT (actual) | ¥81.4bn FY Mar 2026 | Holding | 6.4% margin print. Normalised at FX ¥132 USD/JPY and Sukiya at 7%, the AOP reconstructs to ¥89–92bn FY March 2028. |
| FCF Yield (spot / mid-cycle) | 1.8% / 5–6% | Asymmetric | Spot depressed by FY March 2026 capex peak. Mid-cycle reconstructs to 5–6% on capex normalisation toward 1.1–1.2x D&A. Anchors the SOTP base case lower bound near ¥6,200–7,100. |
| Buyback announcement ≥¥30bn over 3 years | none | Trigger | Bull-confirmation materialisation. Closes 5–10% of the discount versus archetype peers and lifts the Shareholder Alignment pillar. |
| Net debt / EBITDA | 1.86x | Holding | IFRS 16 inflated, lease-adjusted estimated 2.3–2.7x. Capacity for buyback or strategic action exists at current leverage. |
| Forward P/E (consensus) | 23.8x FY27 / 20.7x FY28 | Reference | Inside the archetype A 18–22x corridor on FY28 normalised. Implies recovery template priced ; permanent margin loss not priced. |
| Dividend yield / DPS | 0.96% / ¥75 | Reference | DPS up from ¥50 FY March 2024 to ¥75 FY March 2026 — payout ratio holding at 27%. Yield remains modest in the sub-industry context. |
Two consecutive Sukiya semester margin prints below 5% reframe the dossier toward permanent margin loss and compress fair value toward ¥5,200–5,800. A second contamination incident within 18 months of the first invalidates the Moat pillar at the level recorded ; the MMD infrastructure becomes a structural liability rather than a structural advantage. The first granular International segment disclosure expected at the May 2026 filing, if it prints below 3% segment margin combined with any impairment guidance of ¥30bn or more on Snowfox, Lovary or Hema, acts as the second bear confirmation.
A buyback announcement above ¥30bn over three years closes 5–10% of the discount versus archetype peers on its own and lifts the Shareholder Alignment pillar. Sukiya semester margin sustained above 8% across two consecutive prints confirms a faster-than-template recovery and unlocks the bull case sequence. Hamasushi sustaining revenue growth above 20% across FY March 2027 with segment margin expanding above 9% validates the compounder leg as a structural compensator for the Sukiya mid-cycle.
A new overseas acquisition financed at Net Debt/EBITDA above 3.0x lease-adjusted, prior to stabilisation of the existing international portfolio, would signal a return to the pre-contamination allocation pattern and force complete re-underwriting that this initiation does not attempt. Currently not signalled.
The information provided on this website is for informational and educational purposes only and should not be construed as financial, investment, legal, or tax advice. All content reflects the personal opinions, interpretations, and analyses of the author at the time of writing and is subject to change without notice. Nothing contained herein constitutes, or should be interpreted as, a recommendation, solicitation, or offer to buy or sell any securities, financial instruments, or other investment products. The author is not a licensed financial advisor, broker, or investment professional. Any references to specific assets, markets, or strategies are illustrative in nature and do not constitute personalized investment advice. Investing in financial markets involves risk, including the potential loss of capital. Past performance is not indicative of future results. Readers are solely responsible for their own investment decisions and should conduct their own independent research and due diligence before making any financial commitments. You are strongly encouraged to consult with a qualified financial advisor, legal professional, or other relevant specialist before making any investment or financial decisions. By accessing and using this blog, you agree that the author shall not be held liable for any direct or indirect losses, damages, or consequences arising from the use of, or reliance on, the information presented herein. All content is provided "as is" without any warranties of completeness, accuracy, or reliability.